Table 4.

Recommendations for the treatment of IDA with parenteral iron

	Parenteral iron therapy recommendations
Indications	Intolerance of, or noncompliance with, oral iron preparations Malabsorption Celiac disease with insufficient absorption History of gastrectomy, gastrojejunostomy, and/or bariatric surgery Clinically active inflammatory bowel disease Unresolved bleeding Pregnant women with Hb <10.0 g/dL End-stage renal disease anemia treated with erythropoietin * Moderate (Hb 8.0−10.9 g/dL) to severe (Hb <8.0 g/dL) anemia with significant symptoms
Dosage	Ferric carboxymaltose: 1,000−2,000 mg elemental iron based on the body size and anemia severity Iron sucrose: dose as above (see Fig. 3), 100−200 mg per infusion, 3 times/week
Follow-up	Monitor hemoglobin and iron stores after the first month of treatment

^*Definitions of severity of anemia as defined by WHO, please see Figure 1 for details.

Hb, hemoglobin; IDA, iron deficiency anemia.